Ideaya Biosciences price target raised to $53 from $49 at RBC Capital

RBC Capital raised the firm’s price target on Ideaya Biosciences (IDYA) to $53 from $49 and keeps an Outperform rating on the shares. The firm is positive on the meaningfulness of Ideaya’s successful topline phase 2/3 data in HLA- mUM data, their regulatory strategy for daro’s NDA filing in the second half of 2026, and commercial positioning into a 2027 launch, the analyst tells investors in a research note.